期刊文献+

硼替佐米联合地塞米松治疗多发性骨髓瘤患者的临床分析 被引量:6

下载PDF
导出
摘要 目的探讨硼替佐米联合地塞米松治疗多发性骨髓瘤患者的临床疗效。方法 50例多发性骨髓瘤患者,按照治疗方法不同分为观察组和对照组,每组25例。观察组患者给予硼替佐米联合地塞米松进行治疗,对照组患者给予长春新碱、地塞米松和左旋苯丙氨酸氮芥进行治疗。观察比较两组患者治疗后的临床疗效和不良反应情况。结果治疗后,观察组患者中完全缓解14例,接近完全缓解6例,部分缓解3例,轻微反应1例,无改变1例,疾病进展0例,总有效率为92%。对照组患者中完全缓解9例,接近完全缓解5例,部分缓解2例,轻微反应4例,无改变3例,疾病进展2例,总有效率为64%。观察组总有效率明显高于对照组,差异具有统计学意义(P<0.05);观察组总不良反应发生率(52%)明显低于对照组(72%),差异具有统计学意义(P<0.05)。结论硼替佐米联合地塞米松治疗多发性骨髓瘤,临床疗效显著,不良反应发生率比较低,值得临床广泛推广。
出处 《中国实用医药》 2016年第23期142-143,共2页 China Practical Medicine
  • 相关文献

参考文献7

二级参考文献54

  • 1BLADE J,SAMSON D,REECE D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant[J].Br J Haematol,1998,102:1115-1123.
  • 2HAROUSSEAU J L,ATTAL M,LELEU X,et al.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:results of an IFM phaseⅡstudy[J].Haematologic,2006,91:1498-1505.
  • 3JAGANNATH S,DURIE B G,WOLF J,et al.Bortezomib therapy alone and combination with dexamethasone for previously untreated symptomatic multiple myeloma[J].Br J Haematol,2005,129:776-783.
  • 4吴晓雄,于力,黄文荣,赵瑜,王全顺,薄剑,李菲,高春记.硼替佐米治疗难治/复发性多发性骨髓瘤的疗效观察[J].临床血液学杂志,2007,20(5):268-269. 被引量:14
  • 5Raab MS,Podar K,Breitkreutz L,et al.Multiple myeloma[J].Lancet,2009,374 (9686):324-39.
  • 6Reeder CB,Reece DE,Kukreti V,et al.Cyclophosphamide,bortezomib and dexamethasone induction for newly diagnosed multiple myeloma:high response rates in a phase Ⅱ clinical trial[J].Leukemia,2009,23 (7):1337-1341.
  • 7Hideshima T,Miltiades C,Akiyama M,et al.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341[J].Blood,2003,101 (4):1530-1534.
  • 8Roccaro AM,Hideshima T,Raje N,et al.Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells[J].Cancer Res,2006,66 (1):184-191.
  • 9Harousseau JL,Attal M,Avet-Loiseau H,et al.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase Ⅲ trial[J].J Clin Oncol,2010,28 (30):4621-4629.
  • 10Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348 (26):2609-2617.

共引文献23

同被引文献40

引证文献6

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部